|
DSMB 5 postitive recomendation
|
3
|
Resverlogix Corp.
|
Nov 01, 2017 08:21AM
|
|
Re: We're halted....let the speculation begin
|
3
|
Resverlogix Corp.
|
Jul 25, 2017 08:19AM
|
|
Re: Thoughts on ZCC
|
3
|
Zenith Epigenetics
|
Sep 03, 2021 10:01AM
|
|
Re: More news on the way? They say things happen in 3s.....
|
3
|
Resverlogix Corp.
|
May 24, 2017 10:29AM
|
|
Re: My latest email to IR....
|
3
|
Resverlogix Corp.
|
Apr 16, 2019 07:16PM
|
|
seems to be a lot of competing BP interest in new prostate cancer drugs
|
3
|
Zenith Epigenetics
|
Jan 18, 2018 08:37AM
|
|
Re: Q4 2017 Events
|
3
|
Resverlogix Corp.
|
Oct 21, 2017 11:55AM
|
|
Re: A lesson on futility analyses from the CETP inhibitors
|
3
|
Resverlogix Corp.
|
May 11, 2017 11:29AM
|
|
Re: Yahoo poster claims a reverse split coming....
|
3
|
Resverlogix Corp.
|
Nov 10, 2018 02:07PM
|
|
Re: Why are you invested in RVX
|
3
|
Resverlogix Corp.
|
Jun 18, 2019 04:03PM
|
|
Re: Phase 1b/2 trial expected to initiate 1Q 2019
|
3
|
Zenith Epigenetics
|
Mar 13, 2019 09:23AM
|
|
Re: Sales could take a hit
|
3
|
Resverlogix Corp.
|
Apr 17, 2023 06:41PM
|
|
Re: The Rubicon or the Jordan?
|
3
|
Resverlogix Corp.
|
Apr 10, 2018 04:45PM
|
|
Re: What would an update really tell us?
|
3
|
Resverlogix Corp.
|
Jul 19, 2015 06:26PM
|
|
Re: Trial
|
3
|
Zenith Epigenetics
|
Sep 08, 2016 10:37AM
|
|
Term sheet and enterprise valuation
|
3
|
Zenith Epigenetics
|
Dec 13, 2020 11:24AM
|
|
Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
|
3
|
Zenith Epigenetics
|
Mar 03, 2017 01:25PM
|
|
Re: 3 straight days of declining volume....
|
3
|
Resverlogix Corp.
|
Nov 15, 2019 09:37AM
|
|
Re: ...is anybody out there at the AGM...?
|
3
|
Resverlogix Corp.
|
Oct 01, 2015 11:47AM
|
|
Re: Good post SanFran
|
3
|
Zenith Epigenetics
|
May 28, 2019 01:58PM
|
